• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.

作者信息

Okabe Seiichi, Tauchi Tetsuzo, Ishii Yuko, Akahane Daigo, Nunoda Kousuke, Honda Seiko, Takaku Tomoiku, Ohyashiki Kazuma

出版信息

Int J Hematol. 2007 Feb;85(2):173-4. doi: 10.1532/IJH97.06187.

DOI:10.1532/IJH97.06187
PMID:17321998
Abstract
摘要

相似文献

1
Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
Int J Hematol. 2007 Feb;85(2):173-4. doi: 10.1532/IJH97.06187.
2
Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Int J Hematol. 2005 Apr;81(3):242-5. doi: 10.1532/IJH97.04098.
3
Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.通过监测慢性粒细胞白血病中BCR-ABL转录本水平来调整伊马替尼剂量。
Tohoku J Exp Med. 2006 Dec;210(4):355-63. doi: 10.1620/tjem.210.355.
4
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.对于接受常规剂量伊马替尼治疗但未实现完全细胞遗传学缓解的慢性粒细胞白血病患者，仅增加伊马替尼剂量可带来短暂获益。
Blood. 2003 Oct 1;102(7):2702-3; author reply 2703-4. doi: 10.1182/blood-2003-06-2042.
5
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.高剂量伊马替尼可改善预处理的费城阳性、BCR-ABL 阳性慢性期慢性髓性白血病患者的细胞遗传学和分子缓解：来自随机 CELSG 三期 CML 11“ISTAHIT”研究的初步结果。
Haematologica. 2010 Jun;95(6):908-13. doi: 10.3324/haematol.2009.013979. Epub 2010 Feb 9.
6
New drug targets genetic malfunction in chronic myeloid leukemia.新药针对慢性髓性白血病中的基因功能异常。
Am J Health Syst Pharm. 2001 Jul 15;58(14):1282. doi: 10.1093/ajhp/58.14.1282.
7
Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.甲磺酸伊马替尼剂量递增对细胞遗传学或血液学耐药患者的疗效。
Leuk Lymphoma. 2007 Aug;48(8):1659-61. doi: 10.1080/10428190701474381.
8
Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.甲磺酸伊马替尼诱导一名慢性髓性白血病患者获得持续细胞遗传学缓解，该患者在异基因造血干细胞移植后复发进入淋巴细胞危象。
Int J Hematol. 2004 Jul;80(1):67-9. doi: 10.1532/ijh97.04039.
9
Chronic myeloid leukemia: where do we go now?慢性髓性白血病：我们现在何去何从？
Clin Lymphoma Myeloma. 2009;9 Suppl 4:S374-5. doi: 10.3816/CLM.2009.s.036.
10
Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy.甲磺酸伊马替尼治疗慢性髓性白血病期间出现的巨大粒细胞肉瘤
Am J Hematol. 2006 Jan;81(1):76-7. doi: 10.1002/ajh.20451.

引用本文的文献

1
Molecular monitoring.分子监测
Curr Hematol Malig Rep. 2014 Mar;9(1):1-8. doi: 10.1007/s11899-013-0192-z.

本文引用的文献

1
Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients.转录介导扩增和杂交保护分析在伊马替尼治疗的慢性粒细胞白血病患者中的临床应用价值
Clin Lab Haematol. 2005 Dec;27(6):416-7. doi: 10.1111/j.1365-2257.2005.00723.x.
2
Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.4例慢性髓性白血病患者停用甲磺酸伊马替尼后的结局
Haematologica. 2005 Jul;90(7):979-81.
3
Discontinuation of imatinib therapy after achieving a molecular response.
达到分子反应后停用伊马替尼治疗。
Blood. 2004 Oct 1;104(7):2204-5. doi: 10.1182/blood-2004-04-1335.
4
Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.慢性髓性白血病患者在停用甲磺酸伊马替尼治疗后立即出现甲磺酸伊马替尼敏感的急变期：两例报告
Am J Hematol. 2004 Jul;76(3):275-8. doi: 10.1002/ajh.20096.
5
Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.一名慢性髓性白血病患者停用甲磺酸伊马替尼后出现持续细胞遗传学反应。
Eur J Haematol. 2004 Jun;72(6):441-3. doi: 10.1111/j.1600-0609.2004.00257.x.
6
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.高剂量甲磺酸伊马替尼治疗新诊断的费城染色体阳性慢性期慢性髓性白血病。
Blood. 2004 Apr 15;103(8):2873-8. doi: 10.1182/blood-2003-11-3800. Epub 2003 Dec 24.
7
Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.两名慢性粒细胞白血病患者在达到分子缓解后停用伊马替尼治疗，出现了不同的临床结果。
Leuk Res. 2004 May;28 Suppl 1:S71-3. doi: 10.1016/j.leukres.2003.10.017.
8
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.伊马替尼与干扰素和小剂量阿糖胞苷治疗新诊断慢性期慢性髓性白血病的比较
N Engl J Med. 2003 Mar 13;348(11):994-1004. doi: 10.1056/NEJMoa022457.